Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Teriflunomide increases the likelihood of achieving NEDA in relapsing-remitting MS

Publish date:: March 12, 2020

Key clinical point: Compared with placebo, teriflunomide increases the likelihood that a patient with relapsing-remitting MS will achieve no evidence of disease activity (NEDA).

Major finding: The win ratio of achieving NEDA is 1.33 in favor of teriflunomide.

Study details: An analysis of the TEMSO study, which included 722 patients with relapsing-remitting MS.

Disclosures: The TEMSO study was funded by Sanofi. Several of the investigators received compensation from Sanofi.

Citation:

Edwards KR et al. ACTRIMS 2020, Abstract P036.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,